Compare EUDA & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EUDA | IGC |
|---|---|---|
| Founded | 2021 | 2005 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.0M | 31.5M |
| IPO Year | 2021 | 2005 |
| Metric | EUDA | IGC |
|---|---|---|
| Price | $15.15 | $0.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $55.00 | $5.25 |
| AVG Volume (30 Days) | 4.1K | ★ 924.7K |
| Earning Date | 12-19-2023 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.09 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,271,000.00 |
| Revenue This Year | $134.73 | N/A |
| Revenue Next Year | $195.03 | $13.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.33 | $0.24 |
| 52 Week High | $25.70 | $0.46 |
| Indicator | EUDA | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 50.11 | 67.54 |
| Support Level | $0.94 | $0.31 |
| Resistance Level | $15.36 | $0.36 |
| Average True Range (ATR) | 1.20 | 0.01 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 49.09 | 80.99 |
EUDA Health Holdings Ltd is a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. It offers inventive, accessible, and science-based health solutions to support the shift in regional healthcare from reactive medical treatment to proactive, longevity-focused care. The group also runs a Singapore-based property management business. It operates in two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include management and security services for properties such as condominiums, residential apartments, business office buildings, and shopping malls.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.